Kornimate/medical-research-clean huggingface dataset:
multi-center clinical study on hemoperfusion of kha80

Conditions: Uremia; Uremic Osteodystrophy; Dialysis Related Complication

Summary: to evaluate the decreasing rate of blood il-6, β2-mg and pth in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.

394 patients with maintenance hemodialysis were included in the study, and the blood purification time was ≥8 hours per week (including routine hemodialysis, high-throughput hemodialysis, hemodialysis filtration, hemoperfusion, etc.). randomly assign the control group (197 cases) to receive hemodialysis or hemodialysis filtration treatment, and the frequency of treatment is ≥2 times/week; the experimental group (197 cases) were randomly assigned to receive jianfan kha80 hemoperfusion treatment on the basis of hemodialysis or hemodiafiltration treatment, and the frequency of hemoperfusion treatment was ≥2 times/month. the follow-up data of 0, 4, 12, 24, 36 and 52 weeks of treatment in the two groups were collected, and the information of combined medication and adverse events was also collected.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, regardless of sex; 2. according to the 2012 kdigo guidelines, it was diagnosed as ckd5 (egfr ≦ 15ml/(min ˙ 1.73m2)); 3. receive regular hemodialysis (including hemodialysis filtration) for 4 hours twice a week for ≧3 months; 4. blood β 2-mg ≥ 30 mg/l and/or pth ≥ 600 pg/ml and/or il-6 ≥ 16.2 pg/ml; 5. sign the informed consent form. exclusion criteria: 1. those who are known to have allergic reactions, contraindications or intolerance to the materials of dialyzers and hemoperfutors; 2. patients with severe bleeding tendency and active bleeding, or with definite coagulation dysfunction, with a platelet count of \< 60× 109/l; 3. hemodialysis blood flow \< 200 ml/min. 4. kt/v\<1.2； 5. serum albumin \< 30g/l; 6. parathyroid resection within one year; 7. people with low blood pressure and severe cardiopulmonary insufficiency; 8. lactating or pregnant women or those who plan to be pregnant within one year; 9. infection, history of malignant tumor, active stage of rheumatic immune disease; 10. patients whose life expectancy is less than one year; 11. other clinical researchers are currently or recently (within 30 days); 12. according to the researcher's judgment, the patient has other unsuitable conditions.

Keywords: kha80 maintenance hemodialysis il-6 β2-mg pth
does telephone follow-up improve patients satisfaction

Conditions: Congestive Heart Failure; Angina Pectoris; Pneumonia; Urinary Tract Infection

Summary: several studies have shown the importance of telephone follow-up in reducing hospital readmissions for heart failure. therefore, we aimed in this cohort to investigate whether telephone follow-up with patients discharged from the general internal department improves patients' satisfaction, increases compliance to treatment and reduces adverse effects. patients are recruited from the department of general internal medicine who gave informed consent and could communicate. patients are interviewed by during hospital stay, one and three months later. this group will be compared with patients that are not interviewd by phone aftert hospital discharge.


Eligibility criteria:
inclusion criteria: ability to sign informed consent and communicate by phone in hebrew, arabic, russian or english - exclusion criteria:non of the above -

Keywords: telephone, internal medicine, readmission, patients' satisfaction
experience in predicting decision making for receiving treatment in acute coronary syndrome patients

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to examine the predictability of cognitive representation, emotional responses, and hospitalization experience toward the decision to receive treatment of the acute coronary syndrome patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute coronary syndrome * patients who had first experience or recurrent acute coronary syndrome exclusion criteria: * still have chest pain within 24 hours ago * cognition or communication disorder or having psychotic or neurologic symptoms
voluntary surgical terminations of pregnancy: comparison of the hemorrhagic risk depending on the term

Conditions: Voluntary Termination of Pregnancy

Summary: voluntary termination of pregnancy (abortion) is a major current societal issue. this is a very common situation, around 225,000 abortions are carried out every year in france. the legislation has recently been amended, with the law of march 2, 2022 aimed at strengthening the right to abortion (no. 2022-295) which extended the legal period for voluntary termination of pregnancy from 14 to 16 weeks amenorrhea (as). the national college of french obstetrician gynecologists (cngof), in a press release published on october 12, 2020 in response to the proposed law adopted by the national assembly, wishes to draw attention to the fact that the procedure of surgical abortion between 14 and 16 as changes nature. he states that additional procedures are necessary beyond 14 weeks, which could be a source of complications. in addition, the practice recommendations have not been updated following this extension of time, the centers performing abortions are therefore free regarding the protocol for carrying out these so-called late abortions (between 14 and 16 weeks). there are two pregnancy termination techniques practiced in france: medical or surgical. due to the recent nature of these late abortions, practitioners still have little experience of the consequences of these procedures and this compromises the quality of the information provided to patients. it is necessary to have quality studies to improve knowledge about late-term abortions, in order to be able to correctly inform patients and allow them to make an informed choice regarding the method used. this study follows the modification of the legislation extending the legal period for abortion, with the aim of providing arguments regarding the safety of carrying out surgical abortions at these more advanced stages of pregnancy. in addition, abortion often generates anxiety, the term at which it is carried out could influence the experience of patients. this study would therefore also improve knowledge about the experience of abortion, in order to better support patients throughout their journey.


Eligibility criteria:
inclusion criteria: * woman treated for the performance of a surgical abortion between 10 and 16 weeks (dating by ultrasound) * singleton pregnancy exclusion criteria: * protected adult patient (guardianship, curatorship, safeguard of justice) * refusal to participate expressed by the patient
coil system(ton-bridgemt) for endovascular embolization of cranial aneurysms

Conditions: Intracranial Aneurysms

Summary: the study is a prospective, multi-center, randomized, open, parallel positive control, non-inferiority trial. patients are randomized 1:1 to either coil system(ton-bridgemt) or axium detachable coil(medtronic). the purpose of this study is to assess the safety and effectiveness of the coil system(ton-bridgemt) in the treatment of intracranial aneurysms.


Eligibility criteria:
inclusion criteria: * age 18-80 years. * subject has a target intracranial aneurysm (ia) diagnosed by dsa, and intended to be embolised with coil system. * subject or guardian is able to understand the purpose of study, agrees to comply with protocol requirements and has provided written informed consent. exclusion criteria: * subject is diagnosed as multiple aneurysms. * subject is diagnosed as intracranial bulloid, fusiform, false, dissectimng, infective aneurysm or with arteriovenous malformation. * mrs score≥3. * hunt and hess classification≥4. * subject has emergency ruptured aneurysms and needs assisting stent. * the target aneurysm has received endovascular embolization or surgical treatment. * the aneurysm carrier artery has severe stenosis. * plt\ 1.5. * subject has nonfunction of important organs or other severe diseases. * major surgery in the last 30 days, or intending to receive surgical treatment in 90 days after enrollment. * subject is allergic to antiplatelet drugs, anticoagulants, anesthetics, contrast agents or any related contraindication. * history of allergies to platinum and tungsten. * expected life \<12 months. * pregnant or lactating women. * subject has participated in any other drug or medical device clinical trials in 1 month before writting informed consent . * other circumstances judged by researchers are not suitable for enrollment .
pair production pet imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization

Conditions: Carcinoma, Hepatocellular

Summary: the primary goal of the study is to see if the pet/ct will be able to determine the precise location of the y-90 particles within the liver and within the tumors. we hope to use this information in order to see if these particles distribute evenly throughout large tumors or if the particles go into the tumor which is located in the portal vein. the secondary goals are threefold. first correlate the distribution of y90 particles (as demonstrated by pet/ct) with the degree of dead-tumor tissue. second, see if there is a difference in the y90 particle's distribution when a low particle load (1-3 million particles) is used compared to when a high particle load (6-8 million particles) is used. lastly, compare the sensitivity of standard imaging ( bremsstrahlung imaging) currently being used for the yttrium-90 angioembolization procedure to the sensitivity of the pair production pet research imaging.


Eligibility criteria:
inclusion criteria: 1. uwmc patients over 18 years of age 2. presence of hepatocellular carcinoma greater than 5 cm or presence of tumor-associated portal vein thrombosis. 3. currently undergoing treatment with yttrium-90 radioembolization 4. able to sign informed consent exclusion criteria: 1. patients who are not undergoing treatment with yttrium-90 radioembolization 2. patients unable to provide informed consent

Keywords: pet, yttrium-90
gamified adaptive approach bias modification on individuals with methamphetamine use history

Conditions: Addiction, Substance

Summary: a randomized controlled trial will be conducted to investigate whether a proposed algorithm that adjusts the congruency ratio based on the user's performance and difficulty can enhance the effectiveness of approach bias modification. methamphetamine users will be recruited and randomized into an algorithm group, a standard group, and a control group.

to assess the efficacy of an adaptive approach bias modification (a-apbm) paradigm with gamified designs and dynamic difficulty adjustments in reducing cue-induced craving in individuals with methamphetamine use history. design: randomized controlled trial with three study groups: adaptive apbm (a-apbm), static apbm (s-apbm), and control. a-apbm and s-apbm groups engaged in apbm training using a smartphone application for four weeks. a-apbm used an adaptive algorithm to dynamically adjust the difficulty level based on individual performance, while s-apbm had a static difficulty level. cue-induced craving scores were assessed using a visual analog scale at baseline, post-intervention, and at week-16 follow-up.

Eligibility criteria:
inclusion criteria: • having a history of methamphetamine use of at least one year exclusion criteria: * could not fluently operate an android or an ios smartphone * having mental health conditions other than mud
pain control in dentin hypersensitivity in patients with mih

Conditions: Hypersensitivity Dentin

Summary: this study aims to evaluate the effectiveness of different protocols in controlling dentin hypersensitivity in patients with teeth affected by mih. the subjects will be randomly designated in four experimental groups, according to different treatments. pain will be assessed with the visual analog scale (visual analogue scale - vas), after stimulation with air from the triple syringe and and an exploratory probe at the time of (initial) recruitment, immediately after treatment, after 1 week and 1 month, 3 and 6 months after treatment.


Eligibility criteria:
inclusion criteria: * be between 18 and 35 years old; * present good general health; * present at least one tooth with dentin hypersensitivity reported in the cervical region, which must have a graduated sensitivity equal to or greater than 4 in the vas scale. exclusion criteria: * present active caries lesions or restoration defects in the tooth to be analyzed; * present sufficient dentin loss that requires restorative treatment or periodontal surgery; * volunteers who underwent any professional desensitizer treatment in the last 6 months; * volunteers who used desensitizing pastes in the 3 months; * volunteers who were using anti-inflammatory or analgesic drugs at the time of recruitment; * volunteers who are pregnant or breastfeeding.
study to evaluate the pharmacokinetic interaction and safety after multiple oral doses of fimasartan/amlodipine and rosuvastatin in healthy male subjects

Conditions: Hypertension

Summary: an open-label, fixed-sequence, crossover study to evaluate the pharmacokinetic interaction and safety after multiple oral doses of fimasartan/amlodipine and rosuvastatin in healthy male subjects.

after subjects have signed informed consent voluntarily, they go through screening period for within 28 days. as period i, subjects of cohort1 take fimasartan and amlodipine for 10 days and subjects of cohort2 take rosuvastatin for 6 days. and then, as period ii, subjects of both cohorts take fimasartan, amlodipine and rosuvastatin in cohort1 case for 6 days and in cohort2 case for 10 10days. for fimasartan, subjects of cohort1 have blood sampling 8th, 9th, 14th, 15th day before medication, 10th and 16th day before and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24hour after medication(32 times in total). for amlodipine, subjects of cohort1 have blood sampling 8th, 9th, 14th, 15th day before medication, 10th and 16th day before and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24hour after medication(30 times in total). for rosuvastatin and n-desmethyl rosuvastatin, subjects of cohort2 have blood sampling 4th, 5th, 14th, 15th day before medication, 6th and 16th day before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24hour after medication(28 times in total).

Eligibility criteria:
inclusion criteria: 1. healthy male subject, aged 19- 50 years at screening. 2. body weight within ± 20% of ideal body weight (ibw)(kg) = {height (cm) - 100} \* 0.9 exclusion criteria: 1. history of any illness that may affect the absorption, distribution, metabolism or excretion (hepatobiliary, renal, cardiovascular, endocrine (e.g., hypothyroidism), respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric and musculoskeletal system) 2. hypotension (systolic ≤ 100 mmhg or diastolic ≤ 65 mmhg) or hypertension (systolic ≥ 140 mmhg or diastolic ≥ 90 mmhg), measured at screening 3. active liver disease, or the levels of alt(aspartate transaminase), ast (alanin transaminase) or total bilirubin \> 1.25 x the upper limit of normal 4. history of gastrointestinal disease (i.g., crohn's disease, active peptic ulcer) or resection operation that may affect the absorption of the study drug (excluding simple appendectomy or herniorrhaphy)\] 5. participation in any other study within 3 months prior to the first administration of study drug (the finish time of previous study is the day of the last administration of study drug)

Keywords: fimasartan
multicenter bone and joint health study

Conditions: Osteoarthritis,Knee

Summary: the purpose of this study is to investigate opportunities for prevention and treatment of knee osteoarthritis (oa) by evaluating potentially modifiable risk factors for disease and poor pain and physical function outcomes especially among those with early or mild knee symptoms. the goal of the study is to find novel strategies to prevent disease at an early stage and to limit the impact of disease once it has occurred.

most study participants in the "existing cohort" (3,026 subjects) were enrolled in the original study in 2003-2005. surviving existing cohort participants without end-stage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts. in addition, in 2016-2018 the cohort will be enriched by the recruitment of an additional 1,500 "new cohort" participants with early or mild knee symptoms. the goal of the study is to find novel strategies to prevent disease at an early stage.

Eligibility criteria:
inclusion criteria for "new cohort" participants: * age 45 to 69 years (adult, senior) * males and females * healthy volunteers * community-based sample exclusion criteria for "new cohort" participants: * rheumatoid or inflammatory arthritis (based on self-report and use of medications specific to these conditions) * serious health condition e.g., end-stage renal disease, etc. that would likely limit follow-up to less than 2-3 years * plan to relocate out of geographic region in next 3 years * not able to walk without the aid of a person or assistive device * knee joint replacement surgery in either knee * neither knee fits in the mri knee coil (determined during screening visit). * not competent to give informed consent * advanced structural tibiofemoral or patellofemoral knee oa disease (kl grade 3 or 4) in either knee (determined by knee x-ray screening)
a study investigating the change in metabolism phenotype in paediatric, adolescent & young adults with hodgkin or non-hodgkin lymphoma.

Conditions: Hodgkin Lymphoma; Non Hodgkin Lymphoma

Summary: pegasus aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. the study will be conducted in patients (6-25 years of age) with hodgkin lymphoma or non-hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the cyp3a4, cyp2c19, and cyp2d6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. the study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. the acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.


Eligibility criteria:
inclusion criteria: * age 6-25 years of age. * new diagnosis of hodgkin lymphoma or non-hodgkin lymphoma. * able to swallow and absorb oral or nasogastric tube (ngt) administration of probe drugs. * able to provide written informed consent. exclusion criteria: * failure to comply with inclusion criteria. * has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan). * common terminology criteria for adverse events (ctcae) grade iv end organ dysfunction (i.e., hepatic, renal, gastrointestinal). * had previous oncological treatment (not first cancer diagnosis). * is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent. * any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent. * unable to provide written informed consent.

Keywords: phenoconversion
revive: replens versus intra-vaginal estrogen for the treatment of vaginal dryness on aromatase inhibitor therapy

Conditions: Estrogen Receptor Positive Breast Cancer; Breast Cancer

Summary: this study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called replens.

to evaluate estring versus replens for treatment of atrophic vaginitis in breast cancer survivors on adjuvant aromatase inhibitor therapy. primary objective 1. to compare improvement of atrophic vaginitis signs and symptoms between women on the vaginal estrogen ring and those on replens vaginal cream. 1.1 administer a questionnaire at baseline, 4 weeks, 12 weeks, and 24 weeks to all patients which will assess vaginal dryness and vaginal itching. over six months, we expect that patients who are receiving vaginal estrogen will have more improvement in atrophic vaginitis symptoms as compared to those women on replens. secondary objectives 2.1 assess compliance with aromatase inhibitor (ai) therapy in each arm to see whether vaginal estrogen therapy increases ai compliance among women who have atrophic vaginitis. compliance will be checked by counting pills at clinic visits at 4 weeks, 12 weeks, and 24 weeks during the study treatment period, and then every 6 months for a period of 4.5 additional years, or until completion of aromatase inhibitor therapy. we expect that compliance in the vaginal estrogen arm will be superior to that of the replens arm. women over the age of 18 who have been diagnosed with stage i-iii er+ breast cancer and are currently taking adjuvant ai therapy who also complain of atrophic vaginitis symptoms including vaginal dryness, vaginal itching, frequent urinary tract infections, or dyspareunia are candidates for this study. women also must be post-menopausal as defined by any of the following: age \>55 years, history of bilateral oophorectomy, amenorrhea for 1 year with intact uterus and ovaries, or serum estradiol and fsh concentrations in the post-menopausal range along with either amenorrhea for 6 months or previous hysterectomy.

Eligibility criteria:
inclusion criteria: 1. be female 2. be 18 years of age or older. 3. have stage i-iii er+ breast cancer 4. be post-menopausal as defined by any of the following: age \>55 years, history of bilateral oophorectomy, amenorrhea for 1 year with intact uterus and ovaries, or serum estradiol and fsh concentrations in the post-menopausal range along with either amenorrhea for 6 months or previous hysterectomy. 5. currently take adjuvant ai therapy 6. have vaginal dryness, dyspareunia, or ≥3 urinary tract infections per year since starting ai therapy 7. patients must agree not to use any additional estrogen during the five year study period. however, use of non-estrogen containing lubricants prior to sexual intercourse, or otherwise, is allowed. exclusion criteria: 1. use of any exogenous estrogen within the preceding four weeks 2. current vaginal infection.

Keywords: estrogen receptor positive breast cancer breast cancer